Cerevel Therapeutics Holdings (STU:673) 3-Year EBITDA Growth Rate : -8.30% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Cerevel Therapeutics Holdings 3-Year EBITDA Growth Rate?

Cerevel Therapeutics Holdings's EBITDA per Share for the three months ended in Mar. 2024 was €-0.65.

During the past 3 years, the average EBITDA Per Share Growth Rate was -8.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cerevel Therapeutics Holdings was -8.30% per year. The lowest was -51.20% per year. And the median was -29.75% per year.

Competitive Comparison of Cerevel Therapeutics Holdings's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Cerevel Therapeutics Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerevel Therapeutics Holdings's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cerevel Therapeutics Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cerevel Therapeutics Holdings's 3-Year EBITDA Growth Rate falls into.

Cerevel Therapeutics Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Cerevel Therapeutics Holdings (STU:673) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Cerevel Therapeutics Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Cerevel Therapeutics Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cerevel Therapeutics Holdings (STU:673) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (STU:673) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

CERE:USA

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Cerevel Therapeutics Holdings (STU:673) Headlines

No Headlines